pDONR223-PRKAR2B
(Plasmid
#23667)
-
Depositing Labs
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 23667 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepDONR223
-
Backbone manufacturerInvitrogen
- Backbone size w/o insert (bp) 5005
-
Vector typeGateway Donor vector
Growth in Bacteria
-
Bacterial Resistance(s)Spectinomycin, 50 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert namePRKAR2B
-
Alt nameprotein kinase, cAMP-dependent, regulatory, type II, beta
-
SpeciesH. sapiens (human)
-
Insert Size (bp)1257
-
Entrez GenePRKAR2B (a.k.a. PRKAR2, RII-BETA)
Cloning Information
- Cloning method Gateway Cloning
- 5′ sequencing primer M13pUC-fwd
- 3′ sequencing primer M13rev (Common Sequencing Primers)
Resource Information
-
Addgene Notes
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
The ORF has no Stop codon. This design enables easy recombination into a destination vector to add an epitope tag of choice and Stop codon to the ORF. Do NOT use this plasmid directly for transfections.
A set of 4 custom lentiviral vectors is available ( pLX301 (http://www.addgene.org/25895/) , pLX302 (http://www.addgene.org/25896/) , pLX303 (http://www.addgene.org/25897/) , pLX304 (http://www.addgene.org/25890/) ) to be used to express these ORFs in mammalian cells. These plasmids are not included in the kit and must be ordered separately.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pDONR223-PRKAR2B was a gift from William Hahn & David Root (Addgene plasmid # 23667 ; http://n2t.net/addgene:23667 ; RRID:Addgene_23667) -
For your References section:
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA. Nature. 2010 Dec 16;468(7326):968-72. doi: 10.1038/nature09627 10.1038/nature09627 PubMed 21107320